WO2003038074A1 - Procede d'induction de differenciation de cellules souches de mesoblastes ou de cellules es dans des cellules du systeme nerveux - Google Patents

Procede d'induction de differenciation de cellules souches de mesoblastes ou de cellules es dans des cellules du systeme nerveux Download PDF

Info

Publication number
WO2003038074A1
WO2003038074A1 PCT/JP2001/009510 JP0109510W WO03038074A1 WO 2003038074 A1 WO2003038074 A1 WO 2003038074A1 JP 0109510 W JP0109510 W JP 0109510W WO 03038074 A1 WO03038074 A1 WO 03038074A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
stem cells
cell
nervous system
neural
Prior art date
Application number
PCT/JP2001/009510
Other languages
English (en)
Japanese (ja)
Inventor
Osamu Honmou
Original Assignee
Renomedix Institute Inc.
Teikoku Hormone Mfg.Co.,Ltd.
Mitsui Sumitomo Insurance Care Network Company, Limited
Hitachi,Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renomedix Institute Inc., Teikoku Hormone Mfg.Co.,Ltd., Mitsui Sumitomo Insurance Care Network Company, Limited, Hitachi,Ltd. filed Critical Renomedix Institute Inc.
Priority to PCT/JP2001/009510 priority Critical patent/WO2003038074A1/fr
Priority to PCT/JP2002/003344 priority patent/WO2003038090A1/fr
Priority to US10/493,964 priority patent/US20040259254A1/en
Priority to JP2003540340A priority patent/JP4118236B2/ja
Priority to CA2465653A priority patent/CA2465653C/fr
Priority to PCT/JP2002/011294 priority patent/WO2003038075A1/fr
Priority to EP02775435A priority patent/EP1452586B1/fr
Priority to KR1020047006637A priority patent/KR101022349B1/ko
Priority to CNA028265998A priority patent/CN1610738A/zh
Publication of WO2003038074A1 publication Critical patent/WO2003038074A1/fr
Priority to JP2007319328A priority patent/JP2008119003A/ja
Priority to US12/437,639 priority patent/US20090280564A1/en
Priority to JP2009278621A priority patent/JP2010051326A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/44—Thiols, e.g. mercaptoethanol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Definitions

  • the present invention relates to a method for inducing differentiation from mesoderm stem cells or ES cells into neural cells, and use thereof.
  • Oligodendrocyte (Archer, DR. Et al., Exp Neurol, 1994, 125, 268-77., Blakemore, WF. And Crang, AJ., Dev Neurosci, 1988, 10, , G ⁇ el, M. et al., Ann New York Acad Sci, 1987, 495, 71-85.), Or Schwann cells (Blak emore, WF., Nature, 1977, 266, 68—9. , Blakemore, WF. And Crang, AJ., Dev Neurosci, 1988, 10, 1-11, Honmou, 0. et al., J Neurosc i, 1996, 16, 3199-208.
  • Neural progenitor cells or stem cells obtained from the brain are capable of self-renewal, It is known to differentiate into neurons and glial cells of various cell lineages (Gage, FH. Et al., Proc Natl Acad Sci USA, 1995, 92, 11879-83., Lois, C. and Alvarez- Buyl la, A., Proc Natl Acad Sci USA, 1993, 90, 2074-7., Morshead, CM. Et al., Neuron, 1994, 13, 1071—82., Re ynolds, BA. And Weiss, S , Science, 1992, 255, 1707- 10.).
  • neuronal progenitor cells obtained from the brain were expanded into single cells, and cell lines were cloned in vitro.
  • self-renewal ability ie, proliferative ability
  • multipotency ie, neuron (astrolog tes), oligodendrocytes (oligodendrocytes; oli differentiation into godendr ocy tes
  • the present inventor has a technique for collecting a mononuclear cell fraction from bone marrow cells, umbilical cord blood cells, or fetal liver cells, which is easier than a technique for collecting neural stem cells to obtain donor cells.
  • the present inventor has found that the mononuclear cell fraction prepared from bone marrow cells has the ability to differentiate into neural cells. Further, the present inventor further provides a cell fraction containing mesoderm stem cells isolated from the mononuclear cell fraction, a cell fraction containing stromal cells, and a cell fraction containing AC 133-positive cells. Has been found to have the ability to differentiate into neural cells. Disclosure of the invention
  • the present invention has been made in view of such a situation, and an object of the present invention is to provide a method for inducing differentiation from mesoderm stem cells or ES cells to nervous system cells, a nervous system cell obtained by the method, and the nervous system. It is an object of the present invention to provide a composition for treating a nervous system disease including cells, and a method for treating a nervous system disease using the composition.
  • the inventor newly found that mesodermal stem cells or ES cells contained in a mononuclear cell fraction isolated from bone marrow fluid or umbilical cord blood induce differentiation into neural cells in vitro.
  • mesoderm stem cells or ES cells prepared from a mononuclear cell fraction isolated from bone marrow fluid or umbilical cord blood were added to culture medium 1 (DMEM (Dulbecco's modi fied essential medium) 50%, F -12 50%, FSC 1%, bFGF (Basib fibrobl as t growth f ac tor) 10 ng / ml continuously added caro, EGF (Epidermal growth fact or) 10 ng / ml added daily), or culture solution 2 (NPBM (Neural Progenito r Basal Medium), 2% Neural survival factors (Clonetics)> 0.2% EGF (human Epidermal growth f ac tor) 0.2% Gentami cine-ampho ter ici nB, 0.2% FGF (human fibroblast growth factor), added daily to bFGF 10 ng / ml, in daily addition) the EGF 10 ng / ml, in a state in which floating, 5% C0
  • mesoderm stem cells or ES cells contained in the mononuclear cell fraction isolated from bone marrow fluid or umbilical cord blood are cultured in culture solution 1 (DMEM 50%, F-12 50%, FSC 1%) or culture solution 2 (NPBM (Neural progenitor cell basal medium: Clon etics), 2% Neural survival factors (Clonetics), 0.2% hEGF (human Epidermal growth factor), 0.2% Gentamicine-amphotericinB, 0.2% FGF (human fibroblast growth factor)), and found that mesoderm stem cells or ES cells induce differentiation into neurons or Darya cells It was.
  • culture solution 1 DMEM 50%, F-12 50%, FSC 16%
  • NPBM Neuronuclear cell basal medium: Clon etics
  • hEGF human Epidermal growth factor
  • Gentamicine-amphotericinB 0.2% FGF (human fibroblast growth factor)
  • the nerve regeneration ability of the nervous system cells obtained by the above differentiation induction method was examined in a cerebral infarction model, a dementia model, a spinal cord injury model, and a demyelination model. It turns out that it has the same reproducibility.
  • the present invention is more general, and is considered to be applicable to nerve transplantation / regenerative therapy for wide-area cranial nerve injury. That is, it can be applied to autotransplantation therapy for ischemic cranial nerve injury, traumatic cranial nerve injury, cranial nerve degenerative disease, and metabolic neurological disease of the central nervous system and peripheral nervous system.
  • the differentiation induction method provides a clue to unravel the mechanism of differentiation from mesoderm stem cells or ES cells into nervous system cells. If genes that regulate such differentiation are identified and analyzed, mesoderm stem cells and ES cells can be efficiently and sufficiently transformed into neural cells using these genes. Therefore, it is highly expected that “gene therapy” to promote regeneration of nerve tissue will be possible.
  • the present invention relates to a method for inducing differentiation from mesoderm stem cells or ES cells to neural cells, a nervous system cell obtained by the method, a composition for treating a nervous system disease comprising the neural cell, the composition To treat neurological diseases More specifically about the law,
  • [1] Mesodermal stem cells or ES cells contained in the mononuclear cell fraction isolated from bone marrow fluid or umbilical cord blood collected from vertebrate animals, in a basic culture medium at 33 to 38 ° C. A method of inducing into nervous system cells by culturing with
  • the fraction of mononuclear cells is bone marrow fluid or umbilical cord blood collected from vertebrate animals, and is subjected to density gradient centrifugation in solution for fc at a speed sufficient for the specific gravity at 2000 rpm. After centrifugation, the specific gravity is 1.07
  • the method according to [1] which is a cell fraction that can be prepared by collecting a cell fraction in the range of g / ml to 1. Ig / ml,
  • [4] The method according to any one of [1] to [3], wherein the neural cell is selected from the group consisting of a neural stem cell, a neural progenitor cell, a neural cell, and a glial cell.
  • composition for treating a nervous system disease comprising the cell according to [6],
  • Nervous system diseases include central and peripheral demyelinating diseases, central and peripheral degenerative diseases, stroke, brain tumors, higher dysfunction, mental illness, cancer, traumatic nervous system diseases, and The composition according to [7], which is selected from the group consisting of spinal cord infarction,
  • a method for treating a nervous system disease comprising transplanting the cell according to [6] or the composition according to [7] to a recipient,
  • Nervous system diseases are central and peripheral demyelinating diseases
  • the treatment according to [9] which is selected from the group consisting of peripheral degenerative diseases, stroke, brain tumor, higher dysfunction, mental illness, epilepsy, traumatic nervous system disease, and spinal cord infarction Method,
  • mesoderm stem cells or ES cells contained in a mononuclear cell fraction isolated from bone marrow fluid or umbilical cord blood collected from a vertebrate animal are used in a basic culture solution at 33 ° (: to 38 °).
  • a method for inducing to nervous system cells by culturing under the condition of ° C.
  • the vertebrate is preferably a mammal (eg, mouse, rat, rabbit, buyu, inu, monkey, human, etc.), but is not particularly limited.
  • a mammal eg, mouse, rat, rabbit, buyu, inu, monkey, human, etc.
  • the bone marrow fluid used in the present invention can be collected, for example, by anesthetizing vertebrates (including humans) (local or general anesthesia), inserting a needle into the bone, and sucking with a syringe.
  • the bone include, but are not limited to, the femur, sternum, and iliac bone forming the pelvis.
  • it is an established technique to puncture the umbilical cord directly at birth and suck it with a syringe to collect and store the umbilical cord blood.
  • the mononuclear cell fraction is obtained by subjecting bone marrow fluid or umbilical cord blood collected from a vertebrate to density gradient centrifugation in a solution for a time sufficient for separation according to the specific gravity at 2000 rpm, and after centrifugation, the specific gravity is 1 It can be prepared by collecting cell fractions in the range of 07g / ml to 1.lg / ml.
  • a sufficient time for separation according to specific gravity means a time sufficient for a cell to occupy a position according to its specific gravity in a solution for density gradient centrifugation. Usually, it is about 10 to 30 minutes.
  • the specific gravity of the recovered cell fraction is preferably in the range of 1.07 g / m 1 to 1.08 g / ml (eg, 1.077 g / ml). Density gradient centrifugation As a solution for this, Ficol solution or Percol solution can be used, but is not limited thereto.
  • bone marrow fluid (5-10 zl) collected from a vertebrate is first mixed with a solution (2 ml of 1L-15, 3 ml of Ficol), and centrifuged (2000 rpm for 15 minutes). Extract the nuclear cell fraction (approx. Lml). This mononuclear cell fraction is mixed with a culture solution (2 ml of NPBM) for cell washing and centrifuged again (2000 rpm for 15 minutes). Next, after removing the supernatant, the precipitated cells are collected.
  • the mononuclear cell fraction in the present invention can be used for the preparation of the following mesodermal stem cells even in the state of a culture solution.
  • the mononuclear cell fraction is, for example, culture medium 1 (DMEM (Dulbecco's Modified Eagles Medium-Low Glucose), 103 ⁇ 4 FBS (fetal bovine serum), 1% ant i -biot c-ant imycot ic solution), Medium 2 (MSCBM (Mesenchymal Stem Cel 1 Basal Medium)), 10% MCGS (Mesenchymal Cel 1 Growth Suppl ement), 4 mM L-Glutamine, 1% Penici 11 in-Streptomycin 37) in culture medium 3 (DMEM (sigma), 10% FBS (gibco), 1% Penici 11 in-St reptomycin, 2 mM L-Glutamine (gibco)). It can be prepared by culturing under the conditions of C, 53 ⁇ 4 C0 2 in air.
  • DMEM Dulbecco's Modified Eagles Medium-Low Glucose
  • FBS fetal bovine serum
  • MCGS Me
  • mesoderm stem cells are prepared from the above mononuclear cell fraction (including the state of the culture solution).
  • Mesodermal stem cells refer to cells that constitute a tissue that is developmentally classified as mesoderm, including blood cells.
  • Mesodermal stem cells are cells that have the ability to copy (divide and proliferate) cells that have the same ability as themselves and to differentiate into all the cells that make up the mesoderm tissue. Point to.
  • Mesodermal stem cells have, for example, the characteristics of SH2 (+), SH3 (+), SH4 (+), CD29 (+), CD44 (+), CD14 (-), CD34 (-), CD45 (-) Although it is a cell, it is not particularly limited to these markers.
  • Mesodermal stem cells are, for example, bone marrow fluid or umbilical cord blood collected from vertebrates Centrifugation at 900 g for a time sufficient for separation according to the specific gravity, followed by density gradient centrifugation in the solution, and after centrifugation, the fraction of cells with a specific gravity in the specific gravity range of 1.07 g / ml to 1. lg / ml It is also possible to prepare by recovering.
  • a sufficient time for separation according to specific gravity means a time sufficient for a cell to occupy a position according to its specific gravity in a solution for density gradient centrifugation, usually 10 to 30 About a minute.
  • the specific gravity of the cells to be collected may vary depending on the type of animal from which the cells are derived (eg, human, rat, mouse, etc.).
  • Ficol solution or Percol solution can be used, but is not limited thereto.
  • bone marrow fluid 25 ml or umbilical cord blood collected from a vertebrate is mixed with the same amount of PBS solution, centrifuged (900 g for 10 minutes), and the precipitated cells are mixed with PBS and collected.
  • the cell density is about 4X10 7 cells / ml) to remove blood components.
  • mix 5 ml with Percol solution 1.073 g / ml
  • centrifuge 900 g for 30 minutes
  • the extracted mononuclear cell fraction is mixed with, for example, culture solution 1 (D MEM, 103 ⁇ 4 FBS, anti-biotic-antimycotic solution), culture solution 2 or culture solution 3, and centrifuged ( For 15 minutes at 2000 rpm). Then, the supernatant was removed after centrifugation, the precipitated cells were collected and cultured (37 ° C, 5% CO 2 in air) 0
  • mesoderm stem cells are, for example, from the above mononuclear cell fraction, the above SH 2 (1), SH3 (+), SH4 (+), CD29 (+), CD44 (+), CDH (-) , CD34 ( ⁇ ), CD45 ( ⁇ ) and other cells having cell surface markers can be obtained by selecting using an antibody.
  • the selection method is not particularly limited, and examples thereof include a method using magnet beads or a method using a normal cell sorter (FACS or the like).
  • the method for preparing ES cells in the present invention is well known to those skilled in the art. It can be prepared by the method (Doetschman TC, et al. J Embryol Exp Morphol, 1985, 87, 27-45, Williams RL et al., Nature, 1988, 336, 684-687).
  • the ES cells prepared in this way can be induced to differentiate into neural cells under the conditions described in the examples.
  • the mesoderm stem cell or the ES cell is cultured in a basic culture solution under the conditions of 33 to 38 ⁇ .
  • the basic culture medium in the present invention is not particularly limited as long as it is a normal culture medium used for cell culture, but preferably DMEM (Dulbecco's modi fied essential medi ⁇ ) or NPBM (Neural progenitor cell). basal m edium: CI one tics).
  • the other components of the basic culture solution are not particularly limited, but preferred embodiments include F-12, FSC, Neural survival factors (Clonetics) and the like contained in the culture solution described in Example 2. It is The concentration in these culture media is not particularly limited, but preferably F-12 is 50% and FSC is 1%. Also, C0 2 concentration in the culture solution is good Mashiku is 5%, is not particularly limited.
  • bFGF Basib fibroblast growth factor
  • EGF Extramal growth factor
  • bFGF Basib fibroblast growth factor
  • EGF Extramal growth factor
  • concentration of bFGF or EGF include lng / ml to 100 ng / ml, and preferably 10 ng / ml.
  • timing of addition or the method of addition There are no particular restrictions on the timing of addition or the method of addition, but a method of adding the mesodermal stem cells or the ES cells every day while culturing the mesoderm stem cells or the ES cells in the basic culture solution is preferable.
  • the culture temperature condition in the present invention is 33 ° C to 38 ° C, preferably 37 ° C.
  • the cells may be in a floating state (Neuroscope state) or attached to the culture vessel.
  • Examples of the culture container include a non-coating dish (non-coating dish) and the like.
  • the mesodermal stem cell or the ES cell to the nervous system cell is added. It is possible to promote the induction of In the present invention, such a method for promoting induction into neural cells is also provided.
  • the ischemic brain extract in the present invention can be prepared, for example, by centrifuging a crushed liquid of ischemic brain of a vertebrate. Specifically, the whole brain is removed from an animal model of whole cerebral ischemia (rat, etc.), and the prepared small section is added to NPBM (culture solution for neural stem cells) and mechanically pulverized with a homogenizer. Subsequently, the ischemic brain extract can be prepared by centrifuging at 800 rpm for 5 minutes, collecting the supernatant, and removing cellular components with a membrane filter, but is not limited to this method.
  • the whole cerebral ischemia model animal can be prepared by anesthetizing an animal with Nembutal and then perfusing with physiological saline. The ischemic brain extract thus obtained is added to the basic culture solution containing the basic culture solution and other components. There is no particular limitation on the addition time.
  • the mesoderm stem cells or the ES cells are cultured under the above conditions to induce to the nervous system cells.
  • the nervous system cells include neural stem cells, neural progenitor cells, neural cells, glial cells, and the like.
  • the present invention provides a cell obtained by the above method.
  • the cell is a neuronal cell, and examples thereof include, but are not limited to, neural stem cells, neural progenitor cells, neural cells, and dahlia cells.
  • the present invention also provides a composition for treating a nervous system disease comprising cells obtained by the above method.
  • the cells of the present invention can be used for transplantation as they are, but in order to improve the therapeutic efficiency by transplantation, it is also possible to transplant them as a composition to which various drugs have been added or genes have been introduced.
  • composition of the present invention for example, (1) the addition of a substance that improves the proliferation rate of the cell of the present invention or promotes further differentiation into a nervous system cell, or the introduction of a gene having such an effect (2) Addition of a substance that improves the survival rate of the cells of the present invention in damaged nerve tissue, or introduction of a gene having such an effect (3) Blocks adverse effects of the cells of the present invention from damaged nerve tissue Addition of substances or introduction of genes with such effects, 4 Addition of substances that extend the life of donor cells, or introduction of genes with such effects, 5 Introduction of substances that regulate the cell cycle Addition or introduction of genes with such effects, 6 Addition of substances aiming to suppress immune reactions, or introduction of genes with such effects, 7Energy -Addition of a substance that activates metabolism, or introduction of a gene having such an effect, 8 Introduction of a substance that improves the migration ability of a donor cell in the host tissue, or introduction of a gene having such an effect, 9 Examples include, but are not limited to, introducing a substance that improves
  • Nervous system diseases can be used for the treatment of nervous system diseases by being transplanted into a recipient.
  • Nervous system diseases to be treated For example, central and peripheral demyelinating diseases, central and peripheral degenerative diseases, stroke (including cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage), brain tumors, higher dysfunction including dementia, mental Diseases, epilepsy, traumatic neurological diseases (including head trauma, brain contusion, spinal cord injury), and spinal cord infarction, but are not limited to these.
  • cells obtained by separation from recipient-derived bone marrow fluid or umbilical cord blood can be transplanted as donor cells (autologous transplantation therapy). This is preferable because there is little risk of rejection due to transplantation and there is no difficulty in using an immunosuppressant in combination. If autotransplantation therapy is difficult, cells from other people or other animals can be used. The cells may be stored frozen.
  • cells transplanted to a patient are stored in a syringe in a state where the cells to be transplanted are suspended using artificial cerebrospinal fluid or physiological saline, and the damaged nerve tissue is exposed by surgery.
  • This can be done by direct injection with a needle.
  • the cells of the present invention have high migration ability, they can move in nervous system tissues. Therefore, it may be transplanted near the damaged site.
  • An effect can also be expected by injection into cerebrospinal fluid.
  • cells can be injected with a normal lumbar puncture, there is no need for the patient's surgery, and only local anesthesia is required, which is preferable in that the patient can be treated in a hospital room.
  • it can be expected to be injected into arteries and veins. Therefore, transplantation can be performed in the manner of normal blood transfusion, which is preferable in that transplantation operation in a ward is possible.
  • the cells of the present invention may be used as a gene carrier because of their high migration ability.
  • it is expected to be used as a vector therapy vector for various neurological diseases such as brain tumors.
  • Figure 1 is a photograph showing cultured mesoderm stem cells. It expresses SH3, a marker for mesodermal cells (A), but is negative for nestin, a marker for neural stem cells (B). After differentiation induction under culture conditions, morphologically changed to neural stem cell-like, and the marker of mesoderm cells, SH3, became negative (C) and the neural stem cell marker nestin was positive (D).
  • the scale bar indicates ⁇ ⁇ for A and B, and 200 ⁇ m for C and D.
  • Figure 2 shows that when mesoderm stem cells are induced to differentiate into neural stem cells under culture conditions, and subsequently induced to differentiate, neurons (A, D), astrocytes (B, E), oligodendrocytes (C, F)
  • Photograph showing differentiation into D is a photograph immunostained with NSE (neuron-specific enolase), E 3 ⁇ 4 GFAP (glial fibrillary a cidic protein), and F is GalC (gal actocerebros ide).
  • the scale bar indicates 25 mm.
  • Figure 3 is a photograph showing that the transplanted cells repaired the cerebral infarction.
  • Donor cells that have been induced to differentiate mesoderm stem cells into neural stem cells under culture conditions are genetically marked with the LacZ gene (expresses E. coli galactose seed) and reacts when treated with the substrate X-gal blue Color. Therefore, it is possible to track donor cells in the host brain tissue.
  • Rat brain infarction model (middle cerebral artery temporary occlusion model, basal ganglia, temporal lobe, hippocampus etc. fall into cerebral infarction) transplanted with donor cells marked with LacZ gene, resulting in cerebral infarction
  • the tissue was repaired by engraftment in the basal ganglia, temporal lobe, hippocampus, etc.
  • Figure 4 is a photograph showing that the transplanted cells repaired the spinal cord injury site.
  • the donor cell is not only the damaged site, but also the brain (A), myelin ( B) also migrated to the lumbar spine (C) Repair was done.
  • D, E, and F are photographs of A, B, and C observed at high magnification. The scale bars in A, B, C, D, E and F are 200 m for A, B and C, and 10 xm for D, E and F.
  • Figure 5 is a photograph showing that the transplanted cells repaired the spinal cord demyelination site.
  • A is a photograph showing remyelination after transplantation of neural stem cells derived from adult mesoderm stem cells to a mature rat spinal cord demyelination region.
  • B is a photograph of remyelinated axons observed at high magnification. The scale parameters for A, B, C, D, E and F are 250 m for A, B and C, and 10 m for D, E and F.
  • Fig. 6 is a photograph of a nestin-positive neurosphere, which is a neural stem cell derived from ES cells. BEST MODE FOR CARRYING OUT THE INVENTION
  • the mononuclear cell fraction was added to culture medium 1 (DMEM (Dulbecco's Modified Eagles Medium-Low Glucose) 103 ⁇ 4 FBS (fetal bovine serum), 13 ⁇ 4 anti-biotic-antimycotic solution), culture medium 2, among the liquid 3, and cultured in a 37 ° C, 5% C0 2 conditions, to prepare a culture solution of the mononuclear cell fraction.
  • DMEM Dulbecco's Modified Eagles Medium-Low Glucose
  • FBS fetal bovine serum
  • 13 ⁇ 4 anti-biotic-antimycotic solution fetal bovine serum
  • SH2 (+), SH3 (+), SH4 (+), CD29 (+), CD44 Cells having characteristics such as (+), CD14 (-), CD34 (-), CD45 (-) were extracted using antibodies.
  • a sorting method a method using a magnetic bead or a method using a normal cellosphere (such as FACS) was used.
  • DMEM Dulbecco's modified essential medium
  • F-12 50% FSC 13 ⁇ 4, Basib fibroblast growth factor (bFG F) 10 ng / ml daily, Epidermal Growth factor (EGF) 10 ng / ml added daily
  • culture 2 NPBM (Neural progenitor cell basal medium: Clonetics), 2% Neural survival factors (Clonetics), 0.2% hE GF (human Epidermal growth factor ), 0.2% Gentamicine-amphotericin B, 0.2% hFGF (human fibroblast growth factor) Basib fibroblast growth factor (bFGF) 10 ng / ml, and epidermal growth factor (EGF) 10 ng / ml added daily)
  • DMEM Disulbecco's modified essential medium
  • F-12 50% F-12 50%
  • FSC 13 ⁇ 4 Basib fibroblast growth factor
  • bFG F Basib fibroblast growth factor
  • EGF Epidermal Growth factor
  • NPBM Neuroderma
  • the culture medium of cultured mesoderm stem cells is used as a new culture medium (DMEM (Dulbecco's modified essential medium) 50%, F-12 50%, FSC ⁇ %) or Change to nutrient solution 2 (NPBM (Neural progenitor cell basal medium: Clonetics), 2% Neural survival factors (Clonetics), 0.2% hEGF (human Epidermal growth factor), 0.2% Gentamicine-amphoter icinB, 0.2% hFGF)
  • DMEM Denbecco's modified essential medium
  • NPBM Neurogenitor cell basal medium: Clonetics
  • Neural survival factors Clonetics
  • 0.2% hEGF human Epidermal growth factor
  • 0.2% Gentamicine-amphoter icinB 0.2% hFGF
  • Fig. 1 Induced differentiation from mesoderm stem cells to neural cells, the cultured cells also changed morphologically. Specifically, cells that were single cells formed a neurosphere (Fig. 1). It was also confirmed that neural cells (NSE positive) and glial cells (GFAP positive) differentiated from these neural stem cells (Fig. 2).
  • mesoderm stem cells differentiate into neural stem cells at a high rate. According to this method, it was found that cultured mesoderm stem cells could be induced to neural stem cells at a high rate in just a few days.
  • the rat is deeply anesthetized with Nembutal, then the front chest is opened through the anterior abdominal wall to expose the heart and ascending aorta. An incision is made in the apex and a tube is inserted from the left ventricle into the ascending artery. Next, make an incision in the right atrial appendage, Saline was perfused for 3 minutes to perform full systemic blood removal. After perfusion, it was left as it was for 4 to 5 hours to obtain a whole brain ischemia model. Next, the cerebrum and midbrain were removed from the whole cerebral ischemia model rat and cut into small pieces of about 1 to 2 mm with a pointed knife.
  • the prepared small section was added to NP ⁇ and mechanically pulverized with a homogenizer to prepare a turbid solution.
  • the turbid solution was transferred to a centrifuge tube, centrifuged at 800 rpm for 5 minutes, and the supernatant was collected. Cell components were removed with a 0.22 ⁇ m membrane filter to obtain an ischemic brain extract.
  • NPMM ischemic brain extract medium that had been warmed at 37, and cultured in suspension in 100 ° non-coating dish (IWAKI) at 37 ° C and 5% C02. , BFGF 10 ng / ml and EGF 10 ng / ml were added every day.
  • the supernatant and detached cells were collected in a centrifuge tube with a Pasteur pipette, pipetted several times, and then centrifuged at 1000 rpm for 5 minutes. The supernatant was discarded and NPMM was added to resuspend. Plated on 50% NPMM, 50% ischemic brain extract medium which had been warmed to 37 ° C, 37 ° C, 5 C0 under 2 conditions, and cultured in suspension 100 mm non-coating di sh ( IWAKI). bFGF 10 ng / ml and EGF 10 ng / ml were added every day. Industrial applicability
  • the present invention greatly contributes to the treatment of cerebral infarction, dementia, spinal cord injury, demyelinating disease and the like.
  • the present invention is more general and can be applied to nerve transplantation / regenerative therapy for cranial nerve injury in a wide area.
  • it can be applied to autotransplantation therapy for ischemic cranial nerve injury, traumatic cranial nerve injury, cranial nerve degenerative disease, and metabolic neurological disease of the central and peripheral nervous systems.
  • the differentiation inducing method of the present invention provides a clue to unravel the mechanism of differentiation from mesoderm stem cells or ES cells into neural cells. If genes that regulate such differentiation are identified and analyzed, mesoderm stem cells can be efficiently and sufficiently transformed into neural cells using these genes. . Therefore, “gene therapy” to promote regeneration of nerve tissue It is highly expected that it will be possible.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

On a découvert que lorsque des cellules souches de mésoblastes ou de cellules ES préparées à partir d'une fraction mononucléaire séparée d'un fluide de moelle osseuse ou du sang de cordon ombilical sont cultivées dans un milieu de culture fondamental liquide, la différenciation de ces cellules souches de mésoblastes ou de ces cellules ES dans des cellules du système nerveux ou dans des cellules gliales est induite. On a également découvert que l'induction de la différenciation des cellules souches de mésoblastes ou des cellules ES dans des cellules du système nerveux est favorisée par l'adjonction d'un extrait de cerveau ischémique au milieu de culture fondamental liquide précité. Il est ainsi avéré que les cellules du système nerveux obtenues à l'aide du procédé précité sont capables de régénérer des nerfs dans un modèle d'infarctus cérébral, de démence, de lésion médullaire et de démyélinisation.
PCT/JP2001/009510 2001-10-30 2001-10-30 Procede d'induction de differenciation de cellules souches de mesoblastes ou de cellules es dans des cellules du systeme nerveux WO2003038074A1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
PCT/JP2001/009510 WO2003038074A1 (fr) 2001-10-30 2001-10-30 Procede d'induction de differenciation de cellules souches de mesoblastes ou de cellules es dans des cellules du systeme nerveux
PCT/JP2002/003344 WO2003038090A1 (fr) 2001-10-30 2002-04-03 Procede d'induction de differentiation de cellules souches mesodermiques immortalisees dans les cellules du systeme nerveux
PCT/JP2002/011294 WO2003038075A1 (fr) 2001-10-30 2002-10-30 Procede permettant d'induire une differenciation de cellules souches embroyonnaires mesodermiques, de cellules es ou de cellules immortalisees dans des cellules du systeme nerveux
JP2003540340A JP4118236B2 (ja) 2001-10-30 2002-10-30 中胚葉幹細胞もしくはｅｓ細胞、または不死化した中胚葉幹細胞から神経系細胞への分化誘導方法
CA2465653A CA2465653C (fr) 2001-10-30 2002-10-30 Procede permettant d'induire une differenciation de cellules souches mesodermiques, de cellules es ou de cellules souches mesodermiques immortalisees dans des cellules du systeme nerveux
US10/493,964 US20040259254A1 (en) 2001-10-30 2002-10-30 Method for inducing differentiation mesodermal stem cells, es cells or immortalized cells into nervous system cells
EP02775435A EP1452586B1 (fr) 2001-10-30 2002-10-30 Procede permettant d'induire une differenciation de cellules souches embroyonnaires mesodermiques dans des cellules du systeme nerveux
KR1020047006637A KR101022349B1 (ko) 2001-10-30 2002-10-30 중배엽간세포 혹은 ｅｓ세포, 또는 불사화한중배엽간세포로부터 신경계세포로의 분화유도 방법
CNA028265998A CN1610738A (zh) 2001-10-30 2002-10-30 诱导中胚层干细胞,es细胞,或无限增殖化的中胚层干细胞分化成神经细胞的方法
JP2007319328A JP2008119003A (ja) 2001-10-30 2007-12-11 中胚葉幹細胞もしくはｅｓ細胞、または不死化した中胚葉幹細胞から神経系細胞への分化誘導方法
US12/437,639 US20090280564A1 (en) 2001-10-30 2009-05-08 Method for inducing differentiation of mesodermal stem cells, es cells, or immortalized mesodermal stem cells into neural cells
JP2009278621A JP2010051326A (ja) 2001-10-30 2009-12-08 中胚葉幹細胞を神経系細胞に分化誘導する方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2001/009510 WO2003038074A1 (fr) 2001-10-30 2001-10-30 Procede d'induction de differenciation de cellules souches de mesoblastes ou de cellules es dans des cellules du systeme nerveux

Publications (1)

Publication Number Publication Date
WO2003038074A1 true WO2003038074A1 (fr) 2003-05-08

Family

ID=11737884

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2001/009510 WO2003038074A1 (fr) 2001-10-30 2001-10-30 Procede d'induction de differenciation de cellules souches de mesoblastes ou de cellules es dans des cellules du systeme nerveux
PCT/JP2002/003344 WO2003038090A1 (fr) 2001-10-30 2002-04-03 Procede d'induction de differentiation de cellules souches mesodermiques immortalisees dans les cellules du systeme nerveux

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/003344 WO2003038090A1 (fr) 2001-10-30 2002-04-03 Procede d'induction de differentiation de cellules souches mesodermiques immortalisees dans les cellules du systeme nerveux

Country Status (4)

Country Link
JP (1) JP4118236B2 (fr)
KR (1) KR101022349B1 (fr)
CN (1) CN1610738A (fr)
WO (2) WO2003038074A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098027B2 (en) 2000-06-26 2006-08-29 Renomedix Institute, Inc. Method for remyelinating a demyelinized lesion due to injury in the brain or spinal cord
US10071144B2 (en) 2013-02-06 2018-09-11 Nc Medical Research Inc. Cell therapy for the treatment of neurodegeneration

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101294146B (zh) * 2007-04-28 2011-05-18 中国科学院上海生命科学研究院 诱导神经干细胞分化的系统及诱导方法
KR101540698B1 (ko) 2012-10-05 2015-07-30 사회복지법인 삼성생명공익재단 허혈혈청을 포함하는 줄기세포 활성화 촉진용 조성물 및 줄기세포의 활성화 촉진 방법
CN112746057A (zh) * 2020-12-25 2021-05-04 中国人民解放军海军军医大学 于体外将人多能干细胞诱导为神经中胚层祖细胞并维持自我更新的培养体系、方法及应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2395950A1 (fr) * 1999-12-28 2001-07-05 Kyowa Hakko Kogyo Co., Ltd. Cellules pouvant induire une differenciation dans des cellules du muscle cardiaque

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRUESTLE O. ET AL.: "Embryonic stem cell-derived glial precursors: a source of myelinating transplants", SCIENCE, vol. 285, 1999, pages 754 - 756, XP002907880 *
PITTENGER M.F. ET AL.: "Multilineage potential of adult human mesenchymal stem cells", SCIENCE, vol. 284, 1999, pages 143 - 147, XP000867221 *
SASAKI M. ET AL.: "Transplantation of an acutely isolated bone marrow fraction repairs demyelinated adult rat spinal cord axons", GLIA, vol. 35, no. 1, 2001, pages 26 - 34, XP002945994 *
TREMAIN N. ET AL.: "MicroSAGE analysis of 2,353 expressed genes in a single cell-derived colony of undifferentiated human mesenchymal stem cells reveals mRNAs of multiple cell lineages", STEM CELLS, vol. 19, 2001, pages 408 - 418, XP002907879 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098027B2 (en) 2000-06-26 2006-08-29 Renomedix Institute, Inc. Method for remyelinating a demyelinized lesion due to injury in the brain or spinal cord
US9115344B2 (en) 2000-06-26 2015-08-25 Nc Medical Research Inc. Mesenchymal stem cell and a method of use thereof
US10640749B2 (en) 2000-06-26 2020-05-05 Nc Medical Research Inc. Mesenchymal stem cell and the method of use thereof
US10071144B2 (en) 2013-02-06 2018-09-11 Nc Medical Research Inc. Cell therapy for the treatment of neurodegeneration
US10149894B2 (en) 2013-02-06 2018-12-11 Nc Medical Research Inc. Cell therapy for the treatment of neurodegeneration
US10874723B2 (en) 2013-02-06 2020-12-29 Nc Medical Research Inc. Cell therapy for the treatment of neurodegeneration

Also Published As

Publication number Publication date
WO2003038090A1 (fr) 2003-05-08
KR101022349B1 (ko) 2011-03-22
CN1610738A (zh) 2005-04-27
JPWO2003038075A1 (ja) 2005-02-24
JP4118236B2 (ja) 2008-07-16
KR20040062610A (ko) 2004-07-07

Similar Documents

Publication Publication Date Title
JP4782237B2 (ja) 神経変性疾患の治療薬
CA2315538C (fr) Cellules precurseurs neurales, leur procede de production et leur utilisation pour la therapie d'anomalies neurales
EP1452586B1 (fr) Procede permettant d'induire une differenciation de cellules souches embroyonnaires mesodermiques dans des cellules du systeme nerveux
US20080124701A1 (en) Growth of neural precursor cells using umbilical cord blood serum and a process for the preparation for therapeutic purposes
US20070025973A1 (en) Reprogramming of adult or neonic stem cells and methods of use
WO2010069204A1 (fr) Cellules souches pluripotentes, procédé pour la préparation de celles-ci et utilisations de celles-ci
EP1414947A2 (fr) Cellules souches pluripotentes provenant de tissus peripheriques et leurs utilisations
KR20130119683A (ko) 줄기세포 배양 배지 및 이를 이용한 줄기세포의 배양방법
Chen et al. Neural progenitor cells derived from the adult rat subventricular zone: characterization and transplantation
WO2003038074A1 (fr) Procede d'induction de differenciation de cellules souches de mesoblastes ou de cellules es dans des cellules du systeme nerveux
JP2010051326A (ja) 中胚葉幹細胞を神経系細胞に分化誘導する方法
WO2002014479A2 (fr) Cellules souches neuronales isolees de mammiferes et procedes de fabrication et d'utilisation de ces cellules
EP1650295B1 (fr) Procede de production de cellules tissulaires a partir de cellules souches pluripotentes derivant de cellules epitheliales du pigment de l'iris d'un animal et cellules tissulaires ainsi obtenues
JP2008119003A (ja) 中胚葉幹細胞もしくはｅｓ細胞、または不死化した中胚葉幹細胞から神経系細胞への分化誘導方法
강훈철 Behavioral improvement after transplantation of neural precursors derived from embryonic stem cells into globally ischemic brain of adolescent rats

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP